Sign In
Buy PPD
$47.28
+0 (+0%)
At Close: May 27, 2022
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the opening of a new bioanalytical and biomarker laboratory in Gothenburg, Sweden, locat
Thermo Fisher Scientific's PPD Clinical Research Business Collaborates with HealthVerity to Expand Real-World Data Capabilities
08:30am, Monday, 13'th Apr 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced a strategic data collaboration with HealthVerity, a leading real-world data (RWD) market
Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)
08:00am, Wednesday, 18'th Feb 2026
SALT LAKE CITY, Feb. 18, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective ora
Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
08:00am, Tuesday, 20'th Jan 2026
SALT LAKE CITY, Jan. 20, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective ora
Company on track to report topline results early in the second quarter of 2026 Second planned Data and Safety Monitoring Board (DSMB) meeting evaluated all available safety data for the 82 randomized
Thermo Fisher Scientific Launches PPD CorEvitas Alzheimer's Disease Registry to Advance Real-World Evidence in Neurodegenerative Care
07:37am, Thursday, 18'th Dec 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Launches PPD CorEvitas Alzheimer's Disease Registry to Advance Real-World Evidence in Neurodegenerative Care.
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
08:00am, Tuesday, 18'th Nov 2025
Per the Drug Safety Monitoring Board (DSMB) meeting evaluating one-third of planned participants, study to continue as planned More than half of planned participants have completed dosing with no dose
Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)
08:00am, Tuesday, 30'th Sep 2025
One-Third of Patients Randomized; Topline Results Expected in 2Q 2026 DSMB Safety Review Update Planned for 4Q 2025 SALT LAKE CITY , Sept. 30, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biop
-- Achieved Primary Endpoint with 30mg Dose of RE104 Demonstrating 23.0-Point Reduction from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Score on Day 7, a 5.8-Point Greater Reductio
-- Enrollment Completed on Schedule; Topline Results Expected Q3 2025 -- -- Company to Present Poster Reviewing RE104 Phase 1 Results at the American Society of Clinical Psychopharmacology (ASCP) Annu
NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against PDD Holdings
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
06:30am, Thursday, 14'th Dec 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced ZURZUVAE™ (zuranolone) 50 mg (two 25 mg capsules per day) CIV is now available by p
Brii Biosciences Provides Corporate Update and Reports Full-Year 2022 Financial Results
01:18am, Friday, 24'th Mar 2023
Company maintains priority focus on clinical programs to develop a novel functional cure for hepatitis B viral (HBV) infection and a potential first-of-its-kind treatment for postpartum depression (PP
WILMINGTON, N.C.--(BUSINESS WIRE)--The clinical research business of Thermo Fisher Scientific has won a 2021 TOPRA Award for Regulatory Excellence.
